Be part of the national dialogue about diabetes

November 4, 2015
AOA’s own diabetes guideline honored for contribution to the advancement of eye care.

More than 29 million Americans have diabetes, and 1 in 4 don't know they have it. Doctors of optometry are often the first to detect the tell-tale signs, making it crucial to start the conversation about diabetes with patients.

November is the national diabetes observance month, dedicated to increasing Americans' awareness of a leading public health concern while also promoting a healthy lifestyle. There are numerous ways to capitalize on the open dialogue this month—and year round—and AOA offers the right tools for the job.

AOA diabetes guideline receives distinguished public health award

AOA's first evidence-based clinical practice guideline, Eye Care of the Patient with Diabetes Mellitus—Second Edition (updated 2019) , was recently honored with the American Public Health Association's (APHA) Vision Care Section Outstanding Scientific Paper (Project) Award for 2015. The award recognizes an individual, group or institution that has contributed significantly to the advancement of eye/vision care in the public health field. The guideline, which can be publicly accessed online, offers evidence-based guidance to assist in patient care decisions, but also reaffirms optometry's vital role in the multidisciplinary fight against diabetes.

The guideline represents two and a half years of research and work—with more than 230 academic articles cited—by the AOA Evidence-Based Optometry (EBO) Committee, and over 2,000 hours of optometric volunteer time. The committee adopted a new process set forth in 2011 by the Institute of Medicine, now called the National Academy of Sciences, Engineering and Medicine, to better reflect a shifting health care environment—one in which evidence and outcomes affect everything from care to reimbursement. The new process includes numerous reviewers from multiple disciplines and strict criteria for determining what research is included. The AOA Board of Trustees recently presented the EBO Committee with the AOA Presidential Award, recognizing them for their hard work and dedication in writing evidence-based clinical practice guidelines.

In 2014, the guideline received national recognition when it was posted to the professionally recognized National Guideline Clearinghouse (NGC), a database of clinical guidelines maintained by the Agency for Healthcare Research and Quality of the U.S. Department of Health and Human Services. Guidelines must meet stringent standards to be accepted, and must provide evidence-based recommendations or action plans for patient care. Posting to the clearinghouse means the diabetes guideline is publicly available for other health care professionals, institutions and agencies to reference with knowledge that it has met NGC standards.

AOA's first evidence-based clinical practice guideline, Eye Care of the Patient with Diabetes Mellitus, was recently honored with the American Public Health Association's (APHA) Vision Care Section (VCS) Outstanding Scientific Paper (Project) Award for 2015. Diane Adamczyk, O.D., chair of the AOA's Evidence-Based Optometry Committee, accepts the award, presented by (from left) Janis Winters, O.D., VCS chair elect, Greg Wolfe, O.D., APHA Action Board, and John Crews, O.D., VCS chair.

Related News

Managing the care of patients with contact lens-related dry eye

Contact lens wear has been cited as one of the risk factors for dry eye. Get five expert-recommended tips to help your patients.

Lens-based strategies to address reading issues due to mild, disease-related vision loss

We all see patients with mild vision loss who say their vision does not allow them to read the way they once could. Consider these strategies when refraction doesn’t yield a vision improvement and further disease treatment isn’t warranted.

Restoring sight to the blind? Study shines light on optogenetics in RP

A new study reports partial recovery of visual function in a patient with late-stage retinitis pigmentosa using optogenetic therapy, a first for researchers looking into the neurodegenerative disease.